GlassScriptPhysician profile
Grace K Kim
NPI 1972750370
$10,368.78
in general payments reported to CMS, 2019-2025
26 companies · $2,068 in 2025
The $2,068 reported for 2025 was more than what 89% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $1,875 · 2021: $295 · 2022: $1,408 · 2023: $1,638 · 2024: $2,366 · 2025: $2,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,422 · Consulting Fee: $450 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,422.19 |
| Consulting Fee | $450.00 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $2,007.34 | 2019-2025 | Nemluvio, Aklief |
| Abbvie INC. | $1,921.90 | 2019-2025 | |
| Leo Pharma INC. | $1,065.24 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $717.88 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $698.64 | 2023-2025 | Zoryve |
| Amgen INC. | $551.07 | 2020-2025 | Otezla, Enbrel, Otezla |
| Sun Pharmaceutical Industries INC. | $454.83 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Janssen Biotech, INC. | $400.95 | 2023-2025 | Tremfya |
| Pfizer INC. | $363.56 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $355.45 | 2019-2024 | Dupixent, Libtayo |
| Lilly USA, LLC | $292.84 | 2020-2025 | Taltz, Ebglyss |
| Organon LLC | $268.52 | 2025 | Vtama, Hadlima |
| Allergan, INC. | $217.13 | 2019-2022 | |
| Incyte Corporation | $168.94 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $163.20 | 2019-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $131.95 | 2019-2025 | |
| Ucb, INC. | $110.06 | 2021-2024 | Bimzelx, Cimzia |
| Almirall LLC | $82.38 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $71.34 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $70.20 | 2022-2024 | Sotyktu |
| Dermira, INC. | $67.61 | 2019-2020 | |
| Genentech USA, INC. | $64.37 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $58.97 | 2019-2024 | Duobrii, Siliq |
| Lundbeck LLC | $25.40 | 2025 | Vyepti |
| Revance Therapeutics, INC. | $24.62 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.39 | 2025 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.